TY - JOUR
T1 - Patterns of Care and Outcomes for Small Cell Carcinoma of the Cervix
T2 - A National Retrospective Analysis of 542 Cases
AU - Wharton, David
AU - Kim, Ellen
AU - Pagan, Jonathan
AU - Small, William
AU - Jaboin, Jerry
AU - Ayala-Peacock, Diandra
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Purpose: Small cell carcinoma of the cervix (SCCC) represents 1% to 5% of cervical cancers, with limited data on management and outcomes. We evaluated patterns of care and outcomes for SCCC using the National Cancer Database. Methods and Materials: This retrospective cohort study of SCCC (2004-2011) included 542 cases. Patient demographic, diagnosis, treatment information, and overall survival (OS) were compared with descriptive statistics, logistic regression, Kaplan-Meier, and Cox models. Clinical reasoning was used to select variables for multivariable models to avoid overfitting. Results: SCCC had more comorbidities, higher grade, and advanced stage than other histologies. SCCC received neoadjuvant chemotherapy (36%) more often than squamous cell carcinoma (23%) and adenocarcinoma (13%, P <.001). SCCC had worse OS across all stages (P <.001). Looking at SCCC alone, patients who received chemoradiation (CRT) (with external beam and brachytherapy) and those who received chemotherapy and surgery (without RT) had similar OS (median OS 44 vs 47 months; P =.7) on Kaplan-Meier. Patients receiving CRT were more likely to have stage II or III and N+ disease (P <.001). When evaluating chemoradiation, the addition of brachytherapy resulted in improved median OS (35 vs 19 months; P =.001) regardless of surgical resection status and controlling for age and stage. Even after controlling for stage, age, and comorbidities, the addition of brachytherapy was associated with a 40% improvement in OS (hazard ratio 1.4, 95% confidence interval 1.0-2.0). Conclusions: SCCC patients benefit from chemotherapy with aggressive local treatment. Patients who receive CRT that included brachytherapy did as well as patients who received chemotherapy followed by surgery. Brachytherapy remains an essential component in the treatment of SCCC with CRT.
AB - Purpose: Small cell carcinoma of the cervix (SCCC) represents 1% to 5% of cervical cancers, with limited data on management and outcomes. We evaluated patterns of care and outcomes for SCCC using the National Cancer Database. Methods and Materials: This retrospective cohort study of SCCC (2004-2011) included 542 cases. Patient demographic, diagnosis, treatment information, and overall survival (OS) were compared with descriptive statistics, logistic regression, Kaplan-Meier, and Cox models. Clinical reasoning was used to select variables for multivariable models to avoid overfitting. Results: SCCC had more comorbidities, higher grade, and advanced stage than other histologies. SCCC received neoadjuvant chemotherapy (36%) more often than squamous cell carcinoma (23%) and adenocarcinoma (13%, P <.001). SCCC had worse OS across all stages (P <.001). Looking at SCCC alone, patients who received chemoradiation (CRT) (with external beam and brachytherapy) and those who received chemotherapy and surgery (without RT) had similar OS (median OS 44 vs 47 months; P =.7) on Kaplan-Meier. Patients receiving CRT were more likely to have stage II or III and N+ disease (P <.001). When evaluating chemoradiation, the addition of brachytherapy resulted in improved median OS (35 vs 19 months; P =.001) regardless of surgical resection status and controlling for age and stage. Even after controlling for stage, age, and comorbidities, the addition of brachytherapy was associated with a 40% improvement in OS (hazard ratio 1.4, 95% confidence interval 1.0-2.0). Conclusions: SCCC patients benefit from chemotherapy with aggressive local treatment. Patients who receive CRT that included brachytherapy did as well as patients who received chemotherapy followed by surgery. Brachytherapy remains an essential component in the treatment of SCCC with CRT.
UR - http://www.scopus.com/inward/record.url?scp=85074108601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074108601&partnerID=8YFLogxK
U2 - 10.1016/j.adro.2019.08.008
DO - 10.1016/j.adro.2019.08.008
M3 - Article
AN - SCOPUS:85074108601
SN - 2452-1094
VL - 5
SP - 412
EP - 418
JO - Advances in Radiation Oncology
JF - Advances in Radiation Oncology
IS - 3
ER -